Sichenzia Ross Ference Carmel LLP Represents Titan Partners Group in the $5 Million Registered Direct Offering of Mainz Biomed N.V.
Press Release – New York, NY – November 13, 2023 – Sichenzia Ross Ference Carmel LLP announced today that it represented Titan Partners Group, (the “Company”), an institutional investor, in a $5 million registered direct offering for Mainz Biomed N.V.’s common stock (NASDAQ: MYNZ). As described in the purchase agreement, Mainz Biomed M.V. has agreed to issue 4,166,667 shares of common stock and warrants to purchase up to an aggregate of 4,166,667 shares of common stock (the “Warrants”). The combined effective purchase price for each share of common stock and associate warrant to purchase one share of common stock will be $1.20.
Mainz Biomed M.V. is a Germany-based molecular genetics diagnostic company, specializing in the early detection of cancer. Their flagship product, Coloalert, is a simple and easy-to-use testing kit for early-stage colorectal cancers. Patients receive and send out the completed kit in the mail to a designated lab, making colorectal testing as easy and convenient as it can be.
The Sichenzia Ross Ference Carmel LLP team was led by partners Ross Carmel, Brian Margolis, and law clerk Soumya Cheedi.
Visit SRFC's LinkedIn page
- Sichenzia Ross Ference Carmel LLP Represents Aegis Capital Corp. in the $8.2 Million Private Placement of SOBRsafe, Inc. - October 8, 2024
- Sichenzia Ross Ference Carmel LLP represents A2Z Cust2Mate Solutions Corp. in $4 Million Registered Direct Offering - October 2, 2024
- Sichenzia Ross Ference Carmel LLP represents BriaCell Therapeutics in $5.0 Million Offering - October 2, 2024
